Advantage Alpha Capital Partners LP Catalyst Pharmaceuticals, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $387 Million
- Q4 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 13,050 shares of CPRX stock, worth $298,714. This represents 0.07% of its overall portfolio holdings.
Number of Shares
13,050
Previous 25,196
48.21%
Holding current value
$298,714
Previous $500,000
45.6%
% of portfolio
0.07%
Previous 0.12%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
98.5MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$428 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$193 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$133 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$71.7 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$69 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.35B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...